BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT

BridgeBio Pharma, Inc.

2024-Q1 EPS reported -$0.20 revenue$211,120,000

Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.
Launched BBOT oncology subsidiary with $200M private financing led by Cormorant and Omega.
Secured up to $1.5B via Bayer licensing (up to $310M milestones), royalty financing, and equity.
Acoramidis NDA PDUFA date Nov 29, 2024; EMA MAA accepted, expected approval 2025.
Ended Q1 with $519.8M cash; cash position strengthened significantly.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BridgeBio Pharma, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

BridgeBio Pharma, Inc. reported recent business updates and its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-051573

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.